利托那韦
蛋白酵素
蛋白酶
抗病毒药物
冠状病毒
蛋白酶抑制剂(药理学)
作用机理
生物信息学
药品
病毒复制
体内
病毒学
药理学
化学
体外
2019年冠状病毒病(COVID-19)
酶
生物
病毒
医学
生物化学
病毒载量
传染病(医学专业)
生物技术
病理
疾病
基因
抗逆转录病毒疗法
作者
Mahrokh Marzi,Mohammad Kazem Vakil,Maryam Bahmanyar,Elham Zarenezhad
摘要
In this work, the discovery and description of PF-07321332, a major bioavailable oral SARS-CoV-2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent selection of off-target and in vivo immune profiles are reported. Various drugs and novel compound candidates for the treatment of the COVID-19 pandemic have been developed. PF-07321332 (or nirmatrelvir) is a new oral antiviral drug developed by Pfizer. In response to the pandemic, Pfizer has developed the COVID vaccine and in 2022 will launch its new major anti-SARS-Cov-2 protease inhibitor (PI). The combination of ritonavir and nirmatrelvir is under study in phase III of the clinical trial with a brand name Paxlovid. Paxlovid is an active 3Cl protease inhibitor. Paxlovid exerts its antiviral efficacy by inhibiting a necessary protease in the viral replication procedure. Proteases of coronavirus cleave several sites in the viral polyprotein where pyrrolidone was replaced by flexible glutamine. Due to the coronavirus pandemic, there is high demand for synthesis and development of this novel drug. Herein, we report the synthetic route and the mechanism of action was recently published on nirmatrelvir. Also, a comparison of the performance of two new oral antiviruses (molnupiravir and nirmatrelvir) for the treatment of COVID-19 is described. This review will be helpful for different disciplines such as biochemistry, organic chemistry, medicinal chemistry, and pharmacology.
科研通智能强力驱动
Strongly Powered by AbleSci AI